Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status

Abstract

IntroductionPreemptive therapy (PET) for cytomegalovirus (CMV) reactivation post allogeneic hematopoietic stem cell transplantation (SCT) was shown to decrease the incidence of CMV disease. However, the optimal PET threshold is elusive. Purpose of the studyTo examine the efficacy of PET initiation at a viral threshold of 1000 copies/mL (1560 IU/mL) in a patient population with high prevalence of CMV seropositive status. Patients and methodsA single center retrospective review of patients that underwent allogeneic SCT was done. ResultsA total of 195 allogeneic SCT recipients were included with median follow up of 18.1 (0.7–95.6) months. A total of 178 (91 %) of patients had a positive CMV PCR with median days to initial reactivation post SCT of 17 (1−1187); 129 patients had peak CMV titer < 1000 copies/mL (low titer) whereas the remaining 49 patients had a peak titer ≥ 1000 copies/mL (high titer). 120 (93 %) of patients with low titers cleared spontaneously with median time to clearance of 40 days (4−188). One patient in the high titer group developed CMV disease. At multivariable analysis; age at SCT HR 1.02 (1.004−1.04; 0.017), malignant vs. benign condition HR 9.4 (2.47−61; 0.0005) and cGVHD HR 0.37 (0.2−0.65; 0.0005) were significant for OS. ConclusionsCMV reactivation post SCT was very common in patients with high prevalence of seropositive status. A PET threshold of 1000 copies/mL (1560 IU/mL) appears desirable as it was associated with spontaneous clearance in over 90 % of patients while minimizing treatment related toxicity. Validation of these observations is warranted.